| CTLA-4 in regulatory T cells for cancer immunotherapy N Sobhani, DR Tardiel-Cyril, A Davtyan, D Generali, R Roudi, Y Li Cancers 13 (6), 1440, 2021 | 143 | 2021 |
| Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic … X Sun, R Roudi, T Dai, S Chen, B Fan, H Li, Y Zhou, M Zhou, B Zhu, C Yin, ... BMC cancer 19, 1-13, 2019 | 132 | 2019 |
| Antimicrobial peptides as biologic and immunotherapeutic agents against cancer: a comprehensive overview R Roudi, NL Syn, M Roudbary Frontiers in immunology 8, 305858, 2017 | 127 | 2017 |
| Differential expression of cancer stem cell markers ALDH1 and CD133 in various lung cancer subtypes R Roudi, A Korourian, A Shariftabrizi, Z Madjd Cancer investigation 33 (7), 294-302, 2015 | 88 | 2015 |
| Immunotherapy (excluding checkpoint inhibitors) for stage I to III non‐small cell lung cancer treated with surgery or radiotherapy with curative intent J Zhu, Y Yuan, X Wan, D Yin, R Li, W Chen, C Suo, H Song Cochrane Database of Systematic Reviews, 2021 | 87 | 2021 |
| Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis A Tartarone, G Roviello, R Lerose, R Roudi, M Aieta, P Zoppoli Future Oncology 15 (20), 2423-2433, 2019 | 78 | 2019 |
| Clinical significance of putative cancer stem cell marker CD44 in different histological subtypes of lung cancer R Roudi, Z Madjd, A Korourian, M Mehrazma, S Molanae, MN Sabet, ... Cancer biomarkers 14 (6), 457-467, 2014 | 60 | 2014 |
| Dendritic cell/cytokine‐induced killer cell‐based immunotherapy in lung cancer: what we know and future landscape M Mohsenzadegan, RW Peng, R Roudi Journal of cellular physiology 235 (1), 74-86, 2020 | 59 | 2020 |
| MicroRNA-31 inhibits RhoA-mediated tumor invasion and chemotherapy resistance in MKN-45 gastric adenocarcinoma cells A Korourian, R Roudi, A Shariftabrizi, Z Madjd Experimental Biology and Medicine 242 (18), 1842-1847, 2017 | 47 | 2017 |
| Increased expression of ALDH1A1 in prostate cancer is correlated with tumor aggressiveness: a tissue microarray study of Iranian patients E Kalantari, FH Saadi, M Asgari, A Shariftabrizi, R Roudi, Z Madjd Applied immunohistochemistry & molecular morphology 25 (8), 592-598, 2017 | 46 | 2017 |
| DNA microarray for rapid detection and identification of food and water borne bacteria: from dry to wet lab R Ranjbar, P Behzadi, A Najafi, R Roudi The open microbiology journal 11, 330, 2017 | 46 | 2017 |
| CD44 and CD24 cannot act as cancer stem cell markers in human lung adenocarcinoma cell line A549 R Roudi, Z Madjd, M Ebrahimi, F Samani, A Samadikuchaksaraei Cellular and Molecular Biology Letters 19 (1), 23-36, 2014 | 46 | 2014 |
| CD44 epithelial isoform inversely associates with invasive characteristics of colorectal cancer A Sadeghi, R Roudi, A Mirzaei, A Zare Mirzaei, Z Madjd, M Abolhasani Biomarkers in medicine 13 (6), 419-426, 2019 | 45 | 2019 |
| Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer? G Roviello, L Zanotti, MR Cappelletti, A Gobbi, M Dester, G Paganini, ... Clinical and experimental medicine 18, 15-20, 2018 | 45 | 2018 |
| Expression of cancer stem cell markers OCT4 and CD133 in transitional cell carcinomas S Sedaghat, E Gheytanchi, M Asgari, R Roudi, H Keymoosi, Z Madjd Applied Immunohistochemistry & Molecular Morphology 25 (3), 196-202, 2017 | 45 | 2017 |
| Comparative expression analysis of putative cancer stem cell markers CD44 and ALDH1A1 in various skin cancer subtypes E Erfani, R Roudi, A Rakhshan, MN Sabet, A Shariftabrizi, Z Madjd The International journal of biological markers 31 (1), 53-61, 2016 | 45 | 2016 |
| Clinical significance of endothelial cell marker CD34 and mast cell marker CD117 in prostate adenocarcinoma M Foroozan, R Roudi, M Abolhasani, E Gheytanchi, M Mehrazma Pathology-Research and Practice 213 (6), 612-618, 2017 | 37 | 2017 |
| Lung cancer and β-glucans: review of potential therapeutic applications R Roudi, SR Mohammadi, M Roudbary, M Mohsenzadegan Investigational new drugs 35, 509-517, 2017 | 35 | 2017 |
| Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis F Petrelli, R Ferrara, D Signorelli, A Ghidini, C Proto, R Roudi, MN Sabet, ... Immunotherapy 13 (7), 621-631, 2021 | 34 | 2021 |
| Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients Z Fathi, SAJ Mousavi, R Roudi, F Ghazi PLoS One 13 (7), e0200633, 2018 | 34 | 2018 |
Ahmad ShariftabriziUniversity of IowaVerified email at healthcare.uiowa.edu
